CTRI/2022/01/039211
Not yet recruiting
Phase 3
A Multicentric, Randomized, Double Blind, Parallel Group,Comparative, Active Controlled, Phase-III Clinical Study to Evaluatethe Efficacy, Safety and Tolerability of Fixed Dose Combination(FDC) of Ripasudil 0.4% w/v + Timolol 0.5% w/v Eye Drops versusRipasudil Eye Drops 0.4% w/v and Timolol Eye Drops 0.5% w/vmonotherapy in treatment of elevated intraocular pressure (IOP) insubjects with open angle glaucoma or ocular hypertension
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Health Condition 1: H542- Low vision, both eyesHealth Condition 2: H545- Low vision, one eye
- Sponsor
- Ajanta Pharma Limited
- Status
- Not yet recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Newly diagnosed Male or female subjects aged greater than equal 18 and less than equal 65 years with primary open angle glaucoma or ocular hypertension in at least one eye confirmed by Goldmann applanation tonometry
- •Subjects with IOP between 22 mmHg to 36 mmHg at the time of screening in any one eye In case both the eyes of a single subject are affected then the eye fulfilling the criteria will be considered for the evaluations If both eyes are fulfilling the criteria then the right eye will be considered for the study
- •Best corrected visual acuity 6 by 60 or better
- •Subjects with ability to understand and provide written informed consent form which must have been obtained prior to screening
- •Subjects willing to comply with the protocol requirements
Exclusion Criteria
- •Subjects with known hypersensitivity to any of the components of the formulation
- •Has clinical laboratory evaluations including biochemistry and hematology are not within the reference range for the testing laboratory and the results are deemed clinically significant by the investigator
- •Subjects with known case of any severe or advanced cases of Glaucoma IOP greater than 36 mmHg in either eye
- •Shaffer angle grade less than 2 in either eye range 0 complete or partial closure to 3 wide open angle greater than 20 as measured by Gonioscopy
- •Subjects who are blind or subjects who have a single eye
- •Severe central visual field loss in either eye measured by Perimetry
- •Subjects having central corneal thickness greater than 620 Ã?µm in either eye as measured by Pachymetry
- •Cupdisc ratio greater than 0\.80
- •Subject who are schedule to undergo surgery of the eye during the study period
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 3
Clinical study to treat patients with peripheral neuropathic pain with coexistent Vitamin B12 deficiency with the help of FDC of Gabapentin SR plus Methylcobalamin plus Nortriptyline film-coated bilayered tablets.Health Condition 1: G63- Polyneuropathy in diseases classified elsewhereCTRI/2024/01/062148Ravenbhel Healthcare Pvt. Ltd.
Not yet recruiting
Phase 3
A Study of Combination of Efonidipine Hydrochloride Ethanolate 20 mg/20 mg and Metoprolol Succinate ER 25 mg/ 50 mg Tablets Versus Efonidipine Hydrochloride Ethanolate Tablets 20 mg and Metoprolol Succinate ER Tablets 50 mg Monotherapy for the treatment of Hypertension.CTRI/2018/12/016625Ajanta Pharma Ltd
Not yet recruiting
Phase 3
A Study Metoprolol Succinate plus Cilnidipine plus Telmisartan Tablets in patients for treatment of uncontrolled essential hypertension with stable ischemic heart diseaseCTRI/2018/10/016182Ajanta Pharma Ltd
Completed
Phase 3
A Study of Combination of Azilsartan Medoxomil plus Cilnidipine Tablets for the treatment of subjects with Hypertension.Health Condition 1: I10- Essential (primary) hypertensionCTRI/2019/07/020204Synokem Pharmaceuticals Ltd228
Unknown
Phase 3
A Study of Azelnidipine Tablets for the treatment of subjects with HypertensioCTRI/2019/07/020126Synokem Pharmaceuticals Ltd